Novavax Global Commercial Operations and COVID-19 Vaccine Update
novavax
COVID-19-Influenza Combination (CIC) vaccine: Evaluating dose ranges
of Spike & Hemagglutinin antigens, adjuvant & standalone controls
Phase 2 study underway using a novel Design-of-Experiments approach
Factors
(Variables, Inputs)
Responses
Levels
(Settings)
(Outcomes, Characteristics)
Priority #3
Standalone Formulations
CIC Formulations
SARS-COV-2
Spike Protein
Influenza
Hemagglutinin
(qNIV)
Matrix-MTM
adjuvant
3 doses
3 doses
2 doses
qNIV
only
3 doses
75μg
NVX-CoV2373
only
4 doses
50μg
Licensed influenza
vaccine
2 doses
Performance (%)
100
94%
95
92%
90%
90
88%
85
86%
84%
80
82%
75
80%
Final CIC
Formulation
Factor 2
Factor 1
Response modeling
Designed to enable key antibody and cell-mediated
immunity responses to be used to select one dose for
further development
© 2023 NOVAVAX. All rights reserved.
19View entire presentation